Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (7)

« Back to Publications

Development of a fluorescence-based assay for RecBCD activity using functional data analysis and design of experiments.

Winnifrith A. et al, (2025), RSC Chem Biol, 6, 772 - 779

Chemical proteomics identifies signal peptidase IB (SpsB) as a target of the SOS response inhibitor OXF-077 and a regulator of quinolone resistance emergence in Staphylococcus aureus

Bradbury J. et al, (2025)

Live-Cell Chemoproteomic Profiling Identifies the Uncharacterised Protein YbaA as a Direct Target of Ciprofloxacin in Escherichia coli

Seow T. et al, (2025)

The impact of the COVID-19 pandemic and the changing landscape of CF on the cASPerCF trial: a real-world experience.

Chesshyre ELD. et al, (2024), Trials, 25

Development of an inhibitor of the mutagenic SOS response that suppresses the evolution of quinolone antibiotic resistance.

Bradbury JD. et al, (2024), Chem Sci, 15, 9620 - 9629

Cystic fibrosis transmembrane conductance regulator (CFTR)-targeted therapeutics for cystic fibrosis

Veselu DF. et al, (2024), 239 - 284

A multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPA.

Bradbury JD. et al, (2024), J Cyst Fibros, 23, 354 - 363